Industry & Policy News

[Actimed Therapeutics, Ltd.] The proceeds will be used to fund the continued development of the company and will ensure that preparations remain on track for the global Phase IIb/III IMPACT clinical development program evaluating its lead asset, S-pindolol benzoate in treating cachexia associated with non-small cell lung cancer and colorectal cancer.

[Mainz Biomed NV] Mainz Biomed NV announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA. The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer.

[The White House] The Biden Cancer Moonshot is announcing the launch of “Curing the Uncurable via RNA-Encoded Immunogene Tuning” (CUREIT), a project that aims to develop generalizable mRNA platforms that can be harnessed to train the immune system to more effectively fight cancer and other diseases.

[BiVictriX] BiVictriX Therapeutics plc announced that the United States Patent and Trademark Office has granted a patent providing broad protection for BVX001. The claims granted within this patent provides broad protection for the lead therapeutic asset, BVX001, at the antigen level.

[Cleveland Clinic] The National Institutes of Health recently awarded Cleveland Clinic’s Jacob Scott, MD, DPhil, and collaborators $2.8 million to translate research on how cancer cells evolve and compete into patient care.

[Max Planck Florida Institute] The National Institute on Aging of the NIH has awarded Dr. Yingxue Wang $1,038,819 over three years as part of the Alzheimer’s Disease Initiative Fund.